{"denoms":[{"counts":[{"groupId":"BG000","value":"591"},{"groupId":"BG001","value":"595"},{"groupId":"BG002","value":"1186"}],"units":"Participants"}],"groups":[{"description":"Participants were randomized to 6 mg/kg panitumumab intravenous infusion plus a standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment was administered in cycles every two weeks.","id":"BG000","title":"Panitumumab Plus FOLFIRI"},{"description":"Participants were randomized to receive a standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment was administered in cycles every two weeks.","id":"BG001","title":"FOLFIRI Alone"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.5","value":"60.2"},{"groupId":"BG001","spread":"10.6","value":"60.9"},{"groupId":"BG002","spread":"10.5","value":"60.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"245"},{"groupId":"BG001","value":"219"},{"groupId":"BG002","value":"464"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"346"},{"groupId":"BG001","value":"376"},{"groupId":"BG002","value":"722"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"568"},{"groupId":"BG001","value":"569"},{"groupId":"BG002","value":"1137"}]}],"title":"White or Caucasian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"9"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"}]}],"title":"Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"20"}]}],"title":"Japanese"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}],"title":"Native Hawaiian or Other Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]}],"title":"Aborigine"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"303"},{"groupId":"BG001","value":"294"},{"groupId":"BG002","value":"597"}]}],"title":"Wild-type KRAS"},{"categories":[{"measurements":[{"groupId":"BG000","value":"238"},{"groupId":"BG001","value":"248"},{"groupId":"BG002","value":"486"}]}],"title":"Mutant KRAS"},{"categories":[{"measurements":[{"groupId":"BG000","value":"50"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"103"}]}],"title":"Unevaluable KRAS"}],"description":"KRAS, the human homolog of the Kirsten rat sarcoma-2 virus oncogene","paramType":"NUMBER","title":"KRAS Status","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"179"},{"groupId":"BG001","value":"182"},{"groupId":"BG002","value":"361"}]}],"title":"No"},{"categories":[{"measurements":[{"groupId":"BG000","value":"412"},{"groupId":"BG001","value":"413"},{"groupId":"BG002","value":"825"}]}],"title":"Yes"}],"description":"mCRC: metastatic colorectal cancer","paramType":"NUMBER","title":"Prior Oxaliplatin Exposure for mCRC","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"480"},{"groupId":"BG001","value":"483"},{"groupId":"BG002","value":"963"}]}],"title":"No"},{"categories":[{"measurements":[{"groupId":"BG000","value":"111"},{"groupId":"BG001","value":"112"},{"groupId":"BG002","value":"223"}]}],"title":"Yes"}],"paramType":"NUMBER","title":"Prior Bevacizumab Exposure for mCRC","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"564"},{"groupId":"BG001","value":"565"},{"groupId":"BG002","value":"1129"}]}],"title":"Grade 0 or 1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"57"}]}],"title":"Grade 2"}],"description":"Grade 0: Fully active, able to carry on all pre-disease performance without restriction; Grade 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; Grade 2: Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about \\> 50% of waking hours; Grade 3: Capable of only limited self care, confined to a bed or chair \\> 50% of waking hours; Grade 4: Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; Grade 5: Dead","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"participants"}]}